Imactiv-3D: Our News, Events and Scientific papers

European project IMLINFO: New article published in Cancers
We are thrilled to see our work in the European project IMLINFO finally published in the journal Cancers. IMLINFO’s goal is to determine the efficacy of new immunotherapy treatments against non-Hodgkin’s lymphoma tumours associated with a 3D culture platform. It involves 8 organizations located in Spain and France.
Our research for this project focused on the follicular lymphoma, which accounts for 20-30 percent of all non-Hodgkin lymphoma cases and is still considered as incurable. We conceived a realistic 3D model of t(14;18)-positive B-NHL cell culture, that allows a more robust drug testing by 2D and 3D imaging monitoring techniques.
Imactiv-3D was involved in the 3D characterization of these models using light sheet fluorescence microscopy. This technology has been chosen for its numerous advantages:

It allows to penetrate a 3D sample in depth, quickly and in full,

It exposes a sample to up to 5000 times less energy than confocal fluorescence microscopy, minimizing photo-bleaching and photo-induced cell damage,

It results in high resolution and multichannel fluorescence images.
Imactiv-3D also specifically developed and implemented an image processing pipeline to automatically segment the samples in 3D from light sheet microscopy acquisitions. The algorithm’s output allowed to estimate various 3D morphological parameters as volume, eccentricity, sphericity, and roundness.
The article entitled “3D model characterization by 2D and 3D imaging in t(14;18)-Positive B-NHL: Perspectives for in vitro drug screens in follicular lymphoma” is available here.
24 mar 2021
Conference paper with IPSEN for Toxins 2021

As part of our collaboration, IPSEN Innovation and Imactiv-3D published a conference paper "3D reconstruction and analysis of neuromuscular junction (NMJ) distribution in whole skeletal muscles in the rat using light-sheet microscopy" in Toxicon for the Toxins virtual conferences 2021.
The goal of this work was to get qualitative and quantitative data on the NMJ phenotype to study the Botulinum neurotoxins diffusion after intramuscular administration. An automated image processing methodology, including 3D image denoising and segmentation, was developed to count NMJ.
We used light sheet microscopy to image 5 types of rat muscles and investigate the distribution of NMJ.
You can find the full article here, and read more about this work on our application note "3D ex vivo imaging and characterization of neuromuscular junctions" here.

16 mar 2021
Journée thématique sur les innovations en imagerie cutanée

Imactiv-3D a participé à la 14^ème Journée Thématique sur l’Imagerie Cutanée du 11 mars 2021 organisée par Cosmet’In Lyon et la SF2IC (Société Francophone d’Ingénierie et d’Imagerie Cutanée).
Jean-Michel Lagarde y a présenté une e-conférence sur l'utilisation de différentes modalités d'imagerie pour mesurer la taille des adipocytes sur plusieurs modèles biologiques en s'appuyant sur les travaux effectués avec notre partenaire D.I.V.A. Expertise.
Vous pouvez retrouver le programme de cette journée ici.
Pour en savoir plus sur notre travail pour la dermo-cosmétique, nos fiches d'application sont disponibles ici.

11 mar 2021
CROI 2021: Joint work with the Pasteur Institute on HIV-1

We are proud to see our joint work on HIV-1 with Pasteur Institute being presented by the talented Dr Francesca Di Nunzio during the CROI (Conference on Retroviruses and Opportunistic Infections) happening in March 6-10 2021.
To uncover the HIV-1 DNA fate in the nuclear landscape, they directly tracked the viral DNA and viral RNA by coupling NeoVirTech's HIV-1 ANCHOR^TM technology with RNA FISH or MCP-MS2 RNA-tagging bacterial system.
The computational imaging analysis developed by Imactiv-3D revealed that proviral forms are early located in proximity of the nuclear periphery of mitotic and non-mitotic cells.
This challenging analysis includes localization of viral DNA, viral RNA and various nuclear bodies together with 3D distance estimation on a submicron scale inside nuclei.
Our image processing expert, Renaud Morin, developed a multichannel segmentation algorithm that enables the automatic, precise and robust identification of all these components in 3D.
Based on state-of-the-art image processing methods, this quantification tool paves the way towards refined colocalization study and thus better understanding of HIV mechanisms.
The Pasteur Institute team was able to show that HIV-1 infection restructures nuclear membrane-less organelles (HIV-1 MLOs), enriched in both viral proteins and speckle factors. Integrase proteins are retained in HIV-1 MLOs, while the late retrotranscribed DNA was excluded from them, indicating that those structures are not proviral sites, but orchestrate viral events prior to the integration step. In fact, they show that HIV-1 MLOs are sites of nuclear RT.

6 mar 2021
Imactiv-3D recrute un.e Business Developer
Nous cherchons notre futur.e business developer pour un CDI basé à Toulouse. Vous pouvez candidater directement sur LinkedIN (ici) ou en nous envoyant votre CV et un mail de motivation à contact@imactiv-3d.com.
Vos Missions
Votre objectif principal est de trouver de nouveaux clients et de consolider la base de clients existants. Vous devrez être rapidement autonome pour la relation commerciale et serez accompagné pour les aspects techniques. Vous avez pour mission de développer le chiffre d’affaires dans le secteur européen de la recherche pré-clinique et vous avez la responsabilité et structurer l’offre commerciale auprès des clients.
Prospection client et qualification des contacts (recherche pré-clinique, directeur ou responsable de projets R&D, CSO, entreprise de service CRO, groupe pharmaceutique, sociétés de biotechnologies)

Développer la relation client, gérer le portefeuille client, négocier et conclure les contrats

Assurer un reporting régulier de votre activité

Participer - voire organiser - congrès, salons, présentations, webinaires et rdv B2B

Nous offrons
Une opportunité inégalée de développer votre carrière dans une start-up à forte valeur ajoutée

Une situation stable en CDI

Une rémunération à votre hauteur

Vos Atouts
Formation Bac +3 à 5 type master ou ingénieur complété d’une formation commerciale

Expérience confirmée d’au moins 2 ans en développement commercial dans le milieu de la R&D pharmaceutique et biotechnologique

Idéalement, connaissances techniques ou intérêt dans les domaines de la culture cellulaire 2D/3D, de l’imagerie de fluorescence

Bonne connaissance du tissu économique de l’industrie pharmaceutique

Bon niveau d’anglais courant et scientifique

Bonne organisation, sens des priorités et des opportunités

Autonomie et sens de l’initiative
17 feb 2021
New scientific paper on mitotic arrest effect on clustering of tumor cells

Imactiv-3D was involved in this newly published article investigating the effect of mitotic arrest in the clustering of tumor cells. Our image processing expert, Renaud Morin developed a segmentation algorithm to quantify compaction and other morphology parameters over time. The cluster area was hence monitored and measured at each time point by automated image segmentation with a custom-designed MATLAB routine. This work has been published in Cell Division Journal, in collaboration with the ITAV CNRS labs in Toulouse (France). To read the full article: click here

3 feb 2021
Imactiv-3D recrute un.e technicien.ne en biologie
Nous cherchons un.e technicien.ne en biologie pour un CDD d'une durée de 7 mois à Toulouse. Le poste est à pourvoir dès que possible ! Vous pouvez candidater directement sur LinkedIN (ici) ou en nous envoyant votre CV et un petit mail de motivation à contact@imactiv-3d.com.
Missions
Support technique pour la réalisation des prestations de service et des projets de R&D sous la supervision des ingénieurs responsables en biologie et microscopie.
Sur un plan expérimental, les missions du poste sont :
Ingénierie de modèles de culture cellulaires 3D et optimisation pour la microscopie à feuille de lumière.

Mise en œuvre de techniques de microscopie de fluorescence moyen débit et à feuille de lumière pour l’étude de modèles multicellulaires

Mise en œuvre de différents outils de traitement et d'analyse d'image pour l'analyse des données de microscopie
Activités
Conduire un ensemble de techniques de biologie cellulaire : culture, établissement de lignées cellulaires, cytométrie, immunofluorescence, …

Conduire en adaptant les conditions expérimentales, les expériences d’analyse des modèles 3D par des techniques d’immunohistochimie et en microscopie

Utiliser les logiciels d'analyse d'image

Exploiter et présenter les résultats des analyses, en garantir la qualité

Formaliser et actualiser en accord avec le responsable l’ensemble des protocoles techniques

Assurer la gestion des stocks et des commandes des produits et matériels
Compétences
Connaissance générale en biologie cellulaire et en microscopie

Expérience en culture cellulaire et manipulation des modèles de culture cellulaire 3D

Maîtrise opérationnelle des techniques d’immuno-histologie et immunofluorescence

Connaissance opérationnelle des outils de microscopie

Expérience dans l’utilisation des outils informatiques et des logiciels dédiés au traitement d’images

Savoir rédiger un compte-rendu d’expérience et présenter les résultats

Connaissance des règles d’hygiène et de sécurité liées à la manipulation des produits toxiques, des produits contaminants et des organismes génétiquement modifiés

Savoir rédiger des protocoles et transmettre des savoir-faire techniques
22 jan 2021
Partnership with ThermoFisher scientific

Alzheimer's is the most common cause of dementia, a general term for memory loss and other cognitive disabilities serious enough to interfere with daily life. Alzheimer's has no current cure, but treatments for symptoms are available and research continues to find better ways to treat the disease, delay its onset, and prevent it from developing.
We worked closely with Amylgen, a French Preclinical CRO, to better understand Alzheimer’s and its impact on the brain micro-vascular network. Imactiv-3D created a movie with Amira Software (from Thermo Fisher Scientific) from light sheet microscopy acquisitions and was able to visualize the whole vascular network of a mouse brain in 3D, allowing to study its anatomy in space. The animation scenario could then be applied identically on different conditions in order to make a first reliable visual comparison of global vascular architecture.
In addition to this advanced visual analysis, Imactiv-3D is able to perform 3D quantification studies, confirming the decrease in vascular network density, and modified distribution of vessels size in diseased brains’ cortex.
To learn more about our work on the brain vascular network, you can find our case study here

11 jan 2021
I4ID Congress: Viral infection, replication, propagation and image processing in 2D and 3D

The I4ID (Immunotherapies & Innovations for Infectious Diseases) Congress 2020 will address the current COVID-19 pandemics as well as other infectious diseases. The Scientific Committee has put together a programme focusing on detection, diagnosis, clinical trials, immunotherapies and innovative therapeutic approaches to prevent and tackle infectious diseases.
Franck Gallardo, NeoVirTech's CEO and Jean-Michel Lagarde, Imactiv-3D's CEO, will give a talk during the breakthrough innovation session dedicated to “New approaches to fight infectious diseases" on December 9th, 2020.
The oral presentation entitled “Combination between ANCHORTM tagged viruses and state of the art image acquisition and analysis platforms to investigate virus infection, replication and propagation in living 2D or 3D cell models” will unveil the results obtained by combining ANCHORTM labeling technology with powerful image processing solutions on 2D and 3D models.
Imactiv-3D and NeoVirTech teams will be pleased to meet you during this event and discuss on how our joint service could foster the preclinical development of your vaccines or immunotherapies.

9 dec 2020
Scientific paper on oncolytic viruses in Biomedicines

Our last article in collaboration with NeoVirTech and Transgene has been published in Biomedicines! Franck Gallardo explained "This is the first time that we generate an ANCHOR tagged oncolytic virus that allows rapid investigation of oncolytic potential and discovery of oncolytic modulators."
We were involved in the intracellular quantification of a VACV ANCHOR accumulation, analysis of replication centers (clusters and viral copies number) in two areas (replications centers and cytoplasm).
You can read the entire paper here (DOI:https://doi.org/10.3390/biomedicines8120543)

4 dec 2020
WEBINAR Image processing in 2D and 3D for viral infection and propagation
If you miss on December 2nd, the first joint webinar organized by NeoVirTech and Imactiv-3D about 2D and 3D image processing for virology. "From 2D to 3D quantification: How does image processing enable to decipher viral infection and propagation?"
You can watch the recorded version of the webinar here
Our speakers Franck Gallardo, CEO of NeoVirTech and virology specialist, Renaud Morin, image processing expert at Imactiv-3D, and Jean-Michel Lagarde, CEO of Imactiv-3D will answer those questions:

How to tag the viral genome in real time?

How to image viral replication?

How to extract quantitative data?

How to transpose 2D techniques to live 2D and 3D?

The presentation is illustrated with case studies.
Feel free to contact us if you have any questions regarding the services we can offer as part of our strategic alliance with NeoVirTech in virology, and don't hesitate to follow us on our LinkedIn page to stay tuned about future events and webianrs!
2 dec 2020
Imactiv-3D at the 8th Antibody Industrial Symposium

Our imaging and biology specialist Aurélie Gomes presented our work: A 3D LSFM-based quantitative characterization of antibody penetration in whole tissues during the virtual 8th edition of the Antibody Industrial Symposium the 23rd and 24th of November.
This event gathered academics, big industrials, start-ups and SMEs willing to share and discuss their work on this year’s theme « Multispecific Abs, Ab-like molecules and adoptive cell therapy for fighting diseases ». If you miss this talk or want to rewatch it, you can find it here

23 nov 2020
ICIS 2020: Conference on innovative solutions for Cancer, Aging and Genetic diseases

Our CEO, Jean-Michel Lagarde was one of the speaker for the International Conference on Innovation Solutions (ICIS) organized by International Bio Business Services.
If you miss this remote conference, and want to hear our presentation of "3D imaging quantification of 3D biological models" you can find the recording here.

28 oct 2020
Partnership with Carl Zeiss SAS to offer innovative integrative solution
Imactiv-3D, the innovative CRO that helps preclinical studies get more predictive thanks to its expertise in biology, 3D imaging and image processing, announced that it has entered into a strategic partnership with the 3D imaging and microscopy leader Zeiss. This partnership has been signed simultaneously with the acquisition and installation of a state-of-the-art light sheet microscope in Imactiv-3D’s laboratories.
As the 3D microscopy tends to become a technique that is more and more democratized and accessible, it remains complex and produces a large volume of data, often difficult to process for the users. That is why the alliance between the leader in microscopy and experienced users and image processing engineers is particularly interesting. It allows this technology to be used to its fullest potential and to improve the robustness of the results obtained.
The purpose of this partnership is to provide an integrative and innovative solution to clients needing optimum image acquisition and processing in 3D.
While Zeiss brings its excellence in 3D microscopy and imaging techniques, Imactiv-3D will use its expertise in sample processing for imaging (labelling, optical clearing, conditioning), in 3D imaging (mainly light sheet) and 3D image processing. That alliance thus enables the full potential of the state-of-the-art imaging technology to be exploited and put to best use in preclinical research.
“This partnership is an opportunity for us to be able to offer a complete solution and expertise on the light sheet to our future users, from sample preparation, to 3D analysis, including clearing methods, acquisition and 3D visualization,” said Fabrice Schmitt, Head of Sales for Carl Zeiss SAS.
Jean-Michel Lagarde, founder and CEO of Imactiv-3D, is excited about this unique partnership: “This partnership between the company Carl Zeiss SAS and Imactiv-3D is a great opportunity for the development of our company. It is a recognition of the work accomplished by the team to become experts in light sheet microscopy, in sample preparation and image processing specific to this imaging modality.”
Contact information:
About sample handling, imaging and image analysis: Jean-Michel Lagarde, IMACTIV-3D: jean.michel.lagarde[at]imactiv3d.com

About microscopy: Fabrice Schmitt, Carl Zeiss SAS: fabrice.schmitt[at]zeiss.com

About light sheet microscopy: Emmanuel Elias, Carl Zeiss SAS: emmanuel.elias[at]zeiss.com
21 oct 2020
Imactiv-3D officially joins the Centre Pierre Potier business incubator

After more than 4 years spent in the Centre Pierre Potier hosted by the ITAV CNRS, Imactiv-3D officially joins the business incubator in the same building.
The 5,000m² business incubator is dedicated to the establishment of start-up oriented towards biotechnologies and is located in the campus “Santé du futur” next to the Oncopole in Toulouse (France).

7 jul 2020
Strategic alliance between Imactiv-3D and NeoVirTech
We have the pleasure to announce a new strategic alliance between Imactiv-3D and NeoVirTech.
NeoVirTech has developed a breakthrough technology to directly visualize and quantify in real time virus/viral vector infection and replication in living cells, from high resolution to high content imaging and screening techniques. The company has been elected in the Top10 drug discovery company in Europe in 2019 (PharmaTechOutlook).
This alliance aims to develop a unique platform with both expertise and innovative tools to move virology projects forward with robust data. Our combined clients will not have to do any compromise on scientific excellence.
NeoVirTech will bring its knowledge and know-how in virology, high content screening imaging and its ANCHOR technology to label viruses in living cells, while Imactiv-3D will bring its expertise in non-invasive 3D imaging (light sheet fluorescence microscopy), image processing and 3D cell culture. Over the past years, we have worked together on several projects, leading to scientific papers.
NeoVirTech and Imactiv-3D are now able to perform:

Preclinical evaluation of compounds efficacy on innovative 3D models by monitoring viral infection and replication using state-of-the-art live imaging techniques. A collection of around 30 viruses is available.

3D quantification and visualization of infection (spheroids, organoids, tissues, organs…) combined with staining of a marker of interest. 3D reconstruction for marketing and communication purposes.

“We are delighted to strengthen our partnership with Imactiv-3D. Their expertise and knowledge in the generation of 3D models for imaging and screening application, combined with our expertise in the visualization of infection and replication using autofluorescent viruses will provide unprecedented models for the understanding of virus propagation in complex environments. This new model will have a deep impact in antiviral screening and oncolytic virotherapies validation for example.” Franck Gallardo, Ph.D CEO NeoVirTech SAS
“We are very proud to offer our respective customers the best of both our companies. The stability of Neovirtech's Anchor fluorescent marking technology will allow us to make the most of our expertise in 3D model biology, 3D imaging and image processing. This strategic alliance is an end-to-end solution for all needs in understanding and evaluating the efficacy of antiviral treatments.” Jean-Michel Lagarde, CEO Imactiv-3D
2 jul 2020
WEBINAR Microscopie 3D de la cellule à l'organe : Comment visualiser et quantifier ?

Rendez-vous le 30 juin à 15h, avec notre CEO Jean-Michel Lagarde qui animera un webinar sur la « Microscopie 3D de la cellule à l’organe : Comment visualiser et quantifier ? »
Nous répondrons aux questions suivantes :
- Pourquoi imager en 3D ?
- Comment imager en 3D ?
- Comment exploiter les images obtenues en 3D ?
La présentation sera enrichie d’études de cas.
N’hésitez pas à partager cet événement à vos contacts susceptibles d’être intéressés !
Si vous avez raté ce webinar ou que vous voulez le re-voir, il reste disponible ici

30 jun 2020
Workshop “Mise en lumière des échantillons 3D”

IMACTIV-3D participe au 1^er workshop sur la « Mise en lumière des échantillons 3D » organisé par le CRCT (Centre de Recherche de Cancérologie de Toulouse) à la rentrée prochaine du 14 au 18 septembre 2020.
Notre PDG, Jean-Michel Lagarde, est intervenu pendant ce webinar de préparation, pour présenter l’activité de service en traitement d’image qu’Imactiv-3D mettra à disposition pour les participants.
Vous pouvez retrouver cette présentation ainsi que l’ensemble des interventions des partenaires (CELLINK, IRIT, Miltenyi Biotec, PerkinElmer, ZEISS Microscopy) ici

29 apr 2020
Ph.D. Defense of Aurélie Gomes

On Tuesday, december 17, 2019, Aurélie Gomes successfully defended her thesis entitled "Evaluation of proliferation in tumor spheroids".
Her work, under a CIFRE agreement, is the result of 3 years of intense collaboration between the "Innovation for the study of 3D proliferation - IP3D" team at ITAV - Institut des Technologies Avancées en sciences du Vivant and IMACTIV-3D.
She was particularly interested in the evaluation of the proliferation in the 3D model of tumor spheroids and its regulation, in particular by oxygen. She has implemented experimental approaches to in toto antibody labelling, light sheet imaging and image analysis.
Her work has led to the development of methods and tools of interest in the study of cancer biology and response in anti-tumor pharmacology. Their application shows the importance of physioxia for the study of proliferation and the evaluation of drug response.
We are very happy that Aurélie Gomes continues the adventure with us. She will join IMACTIV-3D as a young doctor in January 2020 to share her expertise with our customers as R&D project manager in biology and imaging.

17 dec 2019
Start of APELYM 3D project

Apelym 3D is a new joint project between IMACTIV-3D and INSERM U1048 aiming to analyze the restoration of lymphatic function and adipose tissue by 3D imaging in context of lymphedema. Imactiv-3D will work to implement innovative tools for 3D imaging specific of the lymphatic network in adipose tissue and facilitate the characterization of the effectiveness of therapeutic targets in preclinical models of lymphedema.
Alongside Imactiv-3D, two teams of INSERM U1048 are involved Florence Tatin (Team 13), coordinator of the project who works on the molecular regulation of lymphangiogenic factors and Philippe Valet (Team 3) who will bring its expertise on adipokines and adipocytes metabolism. While lymphatic capillaries have been well explored in several tissues, less is known about the deeper collecting lymphatic vessels.
Thanks to our complementary expertise, we will be able to explore this lymphatic network on adipose tissues to understand its involvement in lymphedema. Promising targets would be tested as potential actors of the lymphatic network regeneration. This collaborative project is supported by European Fund and Region Occitanie.

1 nov 2019
Imactiv-3D at Termis workshop on 3D Bioprinting for Cancer

The TERMIS-EU workshop is an event organized by INSERM Nantes and the University of Nantes on the 26th and 27th of August 2019 in Nantes (France).
The theme for the workshop is “3D bioprinting in cancer research”. This workshop is intended for medical students, doctors and researchers on oncology. Different themes will be addressed, including “3D bioprinting of tumor models, 3D models for cancer, 3D bioprinting and cancer microenvironment” and “3D bioprinting for tissue reconstruction”. Over the two days, practical workshops on 3D modeling and bioprinting are organized.
Imactiv-3D’s CEO, Jean-Michel Lagarde will make a pitch on Exploration and 3D quantification by light sheet imaging and image processing.
If you are interested in joining us for this workshop, you can register here: www.workshop-termis.eu

26 aug 2019
IMACTIV-3D at the AFSSI connexions in Lyon

Meet Imactiv-3D at the 7th edition annual meeting of preclinical research AFSSI Connexions on July 2-3, 2019 in Lyon (France).
Our CEO, Jean-Michel Lagarde, will be there to present Imactiv-3D’s solutions to support your preclinical research program with innovative imaging and image processing tools. We will be pleased to discuss about your projects and potential collaboration opportunities. Please feel free to contact us to schedule a meeting!
AFSSI Connexions will gather around 300 ecosystem stakeholders during two busy and productive days. Benefit from multiple opportunities to find the know-how, skills, and innovations that you need!
Tuesday July 2: Thematic round table about: Business development strategies, Marketplace, International, Research Tax Credit, Growth and Competitiveness.
Wednesday, July 3: Business convention day and business oriented presentations. Develop your business and relationships with your colleagues, centers of excellence, platforms and sponsors.

2 jul 2019
AIS Tours : 7th Antibody Industrial Symposium
Imactiv-3D will attend the 7^th edition of the Antibody Industrial Symposium (AIS), organized by MabDesign and LabEx MabImprove on June 24-25 2019 in Tours (France). This event is dedicated to Harnessing the Immune System with Therapeutic Antibodies.
During this event, there will be keynote lectures, industrial talks from big pharmaceutical companies and pitch talks of new creative projects, as well as networking and business partnering time.
The topics covered during the congress are:

Immunomodulation via cell membrane antigens

Harnessing the immune system with immunomodulatory therapeutic antibodies

Pitch Session: Immunomodulation with mAbs: new strategies and technologies

Immunomodulation via FC-FcgrammaR interaction

Immunomodulation via soluble antigens
Jean-Michel Lagarde, our CEO, will represent Imactiv-3D, do not hesitate to get in touch to organize a face to face meeting!
24 jun 2019
Imactiv-3D at Meet2Win Oncology Partnering Convention

Meet Imactiv-3D at the Oncology Partnering Convention Meet2Win organized on May 21 and 22, 2019 in Bordeaux (France).
MATWIN organizes the 5th edition of this European Partnering Convention dedicated to open innovation, collaborative research and technology transfer.
MEET2WIN is a business convention combining flash project presentations, conferences, one-to-one business meetings as well as exhibition area.
Jean-Michel Lagarde, our CEO, will be there to discuss about the solutions that Imactiv-3D can offer to oncology research stakeholders.

21 may 2019
IMALC Project Results

The IMALC project comes to an end! This research project was aiming to treat follicular lymphomas with anti-CD20 antibodies, and to develop quantitative imaging tools to evaluate their efficacy by light sheet microscopy.
To conclude, this transversal and interdisciplinary research project made it possible to:
- Characterize biologically relevant study models
- Model lightsheet imaging clinical observations, and maybe in the longer run, to explain why monoclonal antibodies treatments are less effective in patients with high-tumor burden follicular lymphomas or with an increased immune checkpoint expression.
This project is therefore part of a global research effort to better understand lymphomatous pathology and the mechanisms involved in therapeutic treatments in order to identify targets and anticipate resistance mechanisms. This represents a major challenge for a pathology that is currently considered incurable.
Imactiv-3D team has developed a quantitative analysis of the distribution and diffusion of MAb (Monoclonal antibody) on these 3D models of follicular lymphomas (MALC) based on
1) light sheet microscopy imaging of MALC after treatment with therapeutic ACMs and
2) the development of a custom methodology for efficient and automated image processing and analysis to quantitatively characterize the spatiotemporal biodistribution of MAbs within MALC.
This project was based on the skills and expertise found in team N°9 of the CRCT (Toulouse Cancer Research Centre), on the imaging platform of the ITAV (Institut des Technologies Avancées du Vivant) and in the company IMACTIV3D.

31 dec 2018
Joint publication with INSERM in OncoImmunology

Imactiv-3D is very pleased to announce the publication of a new scientific article in the OncoImmunology Journal on follicular lymphoma, resulting from a collaboration with the Unit UMR1037 of the INSERM in Toulouse (France).
The article, entitled “Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma” is already available (DOI: 10.1080/2162402X.2018.1554175). This article presents data providing a rational treatment for follicular lymphoma by PD-1 blockade aimed at boosting γδ T cell anti-tumor functions in this pathology.
Imactiv-3D took charge of the image processing of 3D co-cultured MALC for characterization and quantification of the penetration of γδ T cells and monoclonal antibody (GA101).

17 dec 2018
Scientific publication in virology

Imactiv-3D is pleased to announce the publication of a new scientific article entitled “In vivo labelling of adenovirus DNA identifies chromatin anchoring and biphasic genome replication” in the Journal of Virology (DOI: 10.1128/JVI.00795-18) available here.
This study has been conducted in collaboration with the CNRS UMR5234 lab in Bordeaux (France) and with NeoVirTech. It shows that the real-time genome imaging system developed revealed hitherto uncharacterized features of adenoviral genomes in vivo. This system is capable of identifying new spatiotemporal aspects of the adenovirus life cycle and is potentially transferable to other viral systems with a double-stranded DNA phase.
Imactiv-3D team was involved in the characterization of viral replication centers in human cells and the image processing (denoising and deconvolution).

29 aug 2018
Imactiv-3D to attend the AFSSI Connexions
Imactiv-3D will attend the 6th edition of the AFSSI Connexions, an annual meeting for preclinical research, on July 2-3 2018 in Marseille (France).
Come and meet Jean-Michel Lagarde, our CEO, to enjoy the 2 days of congress, business convention, exposition and presentations organized by the first French R&D center in life sciences!
The AFSSI Connexions program is:

2nd of July: Panel discussions on the following themes: International, Role of competitiveness clusters, logistic, and customer cooperation

3rd of July: Business convention day, workshop and presentations: Commercial and partnership relations with your peers, clusters, platform etc
2 jul 2018
Imactiv-3D Sponsor of the 2nd Workshop BioFabrication & Cancer

The « Canceropole Grand Sud-Ouest » is organizing the 2nd edition of the « Biofabrication & Cancer » workshop on 27 and 28 June 2018 in Bordeaux. This edition will be an opportunity to address a wide scientific audience via 6 sessions on a variety of topics and a strong involvement of industrialists in the bio-impression, modelling and cell culture field (pitchs and demonstrations).
Imactiv-3D is a sponsor of this event that will focus on 3D models for clinical practice the first day, and on bio-inks and technologies and 3D models for cancer the second day. Our CEO, Jean-Michel Lagarde will present a pitch explaining the solutions that Imactiv-3D can offer.

27 jun 2018
Meet2Win 2018

Meet Imactiv-3D at the 4th edition of the Oncology Business Convention Meet2Win organized by MATWIN in Bordeaux (France) on May 17th and 18th 2018.
MATWIN is a French platform supporting innovation in Oncology, subsidiary of Unicancer group (gathering the French Comprehensive Cancer Centers). Meet2Win is a partnering convention fully dedicated to open innovation in Oncology.
This event reunites more than 300 european representatives involved in oncology innovation (pharma, biotechs, startups, investors, researchers, cliniciants, TTOs etc). Jean-Michel Lagarde, our CEO, will be there to talk about our offer for oncology innovation.

17 may 2018
IMLINFO (EFA281/16): Start of the European project

IMLINFO is a cross-border network of personalized immunotherapies against non-Hodgkin's lymphoma (NHL) involving 8 organizations located in Spain and France. Its main objective is to determine the efficacy of new immunotherapy treatments by creating a repository of non-Hodgkin's lymphoma (NHL) tumours associated with a three-dimensional (3D) culture platform.

1 jan 2018
Imactiv-3D at the SF2IC Seminar
Imactiv-3D will attend the 11th edition of the SF2IC Congress organized by the francophone society of engineering and skin imaging (SFIIC) in Marrakech (Morocco) the 22nd and 23th October 2017.
The theme of this event is the bioengineering and objectification of cosmetic effectiveness and it will be addressed during several sessions:

1^stday : 2 sessions about pollution and skin, and bio-engineering of cosmetic effectiveness

2^ndday : 3 sessions about mechanical tension, tissue engineering, and imaging.

Our CEO Jean-Michel Lagarde, will intervene during the 4th session on the 24th October about tissue engineering. He will speak about the imaging of 3D models of skin structures, from adipocyte to reconstructed skin.
23 oct 2017
Imactiv-3D at the INEXO Symposium

Our team will be present at the InExO Symposium in Montpellier on 7 July 2017. This event gathers scientists interested in alternative models in vitro, ex ovo and organisms for pathology and ageing research fields.
The development of these new models is a real challenge to respond to societal concerns through an ethical approach aimed at reducing, optimising and replacing (3Rs: reduce, refine, replace) the use of animals for scientific purposes.
Our CEO, Jean-Michel Lagarde and our Ph.D. student Aurélie Gomes are going to present a poster on a new image analysis-based approach to evaluate cytoxicity on 3D models.
Our procedure using quantitative image analysis allows the evaluation and quantification of anticancer drugs cytotoxic activity on 3D multicellular models, and can be applied to multi-parametric analysis to address customers’ specific needs.

7 jul 2017
Start of IMALC Project on Follicular Lymphomas

The project aims to develop quantitative imaging tools for the evaluation of treatment efficacy of follicular lymphomas using light sheet microscopy. To identify a treatment and evaluate it as objectively as possible requires methods capable of extracting, quantifying and processing information relating to numerous markers. Coupling light sheet microscopy with quantitative image analysis methods directly addresses this need.
This project is co-financed by the ERDF and the Occitanie Region. Imactiv-3D works with two labs: ITAV (CNRS USR3505) and CRCT (INSERM U1037).
The IMALC project aims to carry out an analysis of quantitative distribution and diffusion of monoclonal antibodies (mAbs) on 3D models of lymphomas, based on light sheet microscopy imaging of MALC after treatment with therapeutic monoclonal antibodies and the development of a custom high-performance methodology, automated image processing and analysis to characterize quantitatively the spatiotemporal biodistribution of mAbs within MALCs.
Image: Visualization of a MALC using light sheet microscopy 24h-post treatment with GA101. The color gradient (from blue to white) shows the localization of the GA101 intensity.

1 jan 2017
Imactiv-3D first scientific publication

Imactiv-3D is very proud to announce its first scientific publication in the Oncology Letters!
This scientific article, entitled "Evaluation by quantitative image analysis of anticancer drug activity on multicellular spheroids grown in 3D matrix" is available here (DOI: 10.3892/ol.2016.5221).
Our team developed a new procedure to visualize, analyze and quantify the pharmacological activity of drugs on 3D multicellular spheres grown in a physiological matrix.
The aim of this study was to propose a robust and efficient imaging and analysis pipeline to assess with quantitative parameters the efficacy of a particular cytotoxic drug. HCT116 colorectal adenocarcinoma tumor cell multispheres were observed with structured illumination 3D microscopy and the images obtained were processed with custom analysis tools.
We were thus capable of automatically detecting spheres in a large volume of matrix in 96-well plates. This procedure was used to evaluate drug efficacy in HCT116 spheroids treated with different concentrations of topotecan, a DNA topoisomerase inhibitor. This work demonstrates that quantitative image analysis is an effective mean to evaluate and quantify the cytostatic and cytotoxic activities of anticancer drugs on 3D multicellular models grown in a physiological matrix.

12 dec 2016
Establishment of the company

Hosting of the company within the CNRS in Toulouse (National Centre for Scientific Research).

13 nov 2015